 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Fellow, Department of Pharmacy Practice, School of Pharmacy, University of Mississippi, Jackson, MS
Assistant Professor of Pharmacy, Pharmaceutical Sciences, and Pediatrics, Colleges of Pharmacy and Medicine, University of Tennessee, Memphis, TN
Associate Professor, Departments of Medicine and Pharmacy Practice, Schools of Medicine and Pharmacy, University of Mississippi
Professor of Medicine and Associate Professor of Microbiology, School of Medicine, Departments of Medicine and Microbiology, University of Mississippi Medical Center, Jackson, MS
Reprints: Margaret M Pearson PharmD, Department of Pharmacy Practice, School of Pharmacy, University of Mississippi, 2500 N. State St., Jackson, MS 39216-4505, FAX 601/984-2618, E-mail mpearson{at}pharmacy.umsmed.edu
OBJECTIVE: To review the pharmacology, in vitro susceptibility, pharmacokinetics, clinical efficacy, and adverse effects of voriconazole, a triazole antifungal agent.
DATA SOURCES: A MEDLINE search, restricted to English language, was conducted from 1990 to June 2002. Supplementary sources included program abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America from 1996 to 2001 and manufacturer information available through the Food and Drug Administration's Web site.
DATA EXTRACTION: All published and unpublished trials and abstracts citing voriconazole were selected.
DATA SYNTHESIS: Voriconazole has shown in vitro activity against many yeasts and a variety of mold and dermatophyte isolates. Voriconazole can be administered either orally or parenterally. It exhibits good oral bioavailability, wide tissue distribution including distribution into the central nervous system, and hepatic metabolism. Drug interactions occur through inhibition of the CYP2C9, CYP2C19, and CYP3A4 isoenzymes, resulting in alterations in kinetic parameters of either voriconazole or the interacting agent. Efficacy has been illustrated in open, noncomparative studies of aspergillosis in immunocompromised patients. Human case reports describe successful treatment of rare fungal pathogens. The most commonly reported adverse events include visual disturbances and elevations in liver function tests.
CONCLUSIONS: Voriconazole is at least as effective as amphotericin B in the treatment of acute invasive aspergillosis in immunocompromised patients. It has similar efficacy as fluconazole in treatment of esophageal candidiasis. Voriconazole did not achieve statistical non-inferiority to liposomal amphotericin B for empirical therapy in patients with neutropenia and persistent fever, diminishing enthusiasm for use in this indication until additional trials are completed. Based on case reports and in vitro efficacy, voriconazole may prove to be a clinically useful agent in the treatment of other fungal disease.
Key Words: antifungal, voriconazole
Published Online, February 9, 2003. www.theannals.com, DOI 10.1345/aph.1C261
This article has been cited by other articles:
|
|
 |
|
  M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods J. Clin. Microbiol., January 1, 2007; 45(1): 70 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A Ghannoum, F. C. Odds, M. G. Rinaldi, et al. Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints. J. Clin. Microbiol., March 1, 2006; 44(3): 819 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Balashov, R. Gardiner, S. Park, and D. S. Perlin Rapid, High-Throughput, Multiplex, Real-Time PCR for Identification of Mutations in the cyp51A Gene of Aspergillus fumigatus That Confer Resistance to Itraconazole J. Clin. Microbiol., January 1, 2005; 43(1): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Robatel, M. Rusca, C. Padoin, O. Marchetti, L. Liaudet, and T. Buclin Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient J. Antimicrob. Chemother., July 1, 2004; 54(1): 269 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, A. Barry, J. Bille, S. Brown, D. Ellis, J. F. Meis, R. Rennie, M. Rinaldi, T. Rogers, and M. Traczewski Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue J. Clin. Microbiol., April 1, 2004; 42(4): 1716 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-B. Stern, P. Girard, and R. Caliandro Pleural Diffusion of Voriconazole in a Patient with Aspergillus fumigatus Empyema Thoracis Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1065 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Groll, H. Kolve, K. Ehlert, M. Paulussen, and J. Vormoor Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation J. Antimicrob. Chemother., January 1, 2004; 53(1): 113 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie Infections in Patients with Hematological Cancer: Recent Developments Hematology, January 1, 2003; 2003(1): 438 - 472. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
